To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation

Summary

This is a phase 1, open-label, dose escalation and cohort expansion study and conducted in China and the United States to investigate the safety, tolerability and preliminary efficacy of QLH11811 in advanced or metastatic NSCLC patients who have progressed after prior EGFR-TKI treatment. The study consists of the following 2 phases: phase 1: dose escalation (1a) and phase 2: cohort expansion (1b).

Timeline

Start

2022-10-25

Primary completion

2024-12-31

Completion

2025-12-31

Drugs

Indications